Skip to content
Homepage
Author:
Polaryx Therapeutics, Inc.
Posted Date:
May 28, 2026
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics, Inc.
May 28, 2026
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Polaryx Therapeutics, Inc.
May 14, 2026
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
Polaryx Therapeutics, Inc.
April 23, 2026
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Polaryx Therapeutics, Inc.
April 21, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Polaryx Therapeutics, Inc.
April 15, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
Polaryx Therapeutics, Inc.
April 1, 2026
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
Polaryx Therapeutics, Inc.
March 17, 2026
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
Polaryx Therapeutics, Inc.
March 12, 2026
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
Polaryx Therapeutics, Inc.
February 27, 2026
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics, Inc.
February 17, 2026
1
2
Next
